A prospective cohort study of methotrexate plus idarubicin in newly diagnosed primary CNS lymphoma.

Li, Qing; Ma, Yan; Lin, Zhiguang; Ma, Jingjing; Kang, Hui; Zhang, Mengxue; Xu, Huiwen; Chen, Bobin

Li, Qing; Ma, Yan; Lin, Zhiguang; Ma, Jingjing; Kang, Hui; Zhang, Mengxue; Xu, Huiwen; Chen, Bobin.

Afiliação

Li Q; Department of Hematology, Huashan Hospital, Shanghai, China.
Ma Y; Department of Hematology, Huashan Hospital, Shanghai, China.
Lin Z; Department of Hematology, Huashan Hospital, Shanghai, China.
Ma J; Department of Hematology, Huashan Hospital, Shanghai, China.
Kang H; Department of Hematology, Huashan Hospital, Shanghai, China.
Zhang M; Department of Hematology, Huashan Hospital, Shanghai, China.
Xu H; Institutes of Biomedical Sciences, Fudan University, Shanghai, China.
Chen B; Department of Hematology, Huashan Hospital, Shanghai, China. bbchen@fudan.edu.cn.

J Neurooncol ; 163(1): 39-46, 2023 May.

Article em En | MEDLINE | ID: mdl-35733032

Assuntos

Neoplasias do Sistema Nervoso Central; Linfoma; Humanos; Metotrexato/efeitos adversos; Idarubicina/uso terapêutico; Estudos Prospectivos; Neoplasias do Sistema Nervoso Central/patologia; Linfoma/tratamento farmacológico; Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos; Estudos Retrospectivos

Palavras-chave

Chemotherapy; High-dose methotrexate; Idarubicin; Primary central nervous system lymphoma; Prognosis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias do Sistema Nervoso Central / Linfoma Tipo de estudo: Diagnostic_studies / Etiology_studies / Observational_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google